Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.

Br J Cancer · 2004 · PMC2409647 · PMID 15026791

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The results for fractures did not reach statistical significance in contrast to the data for i.v. ibandronate ( Body et al , 2003a ), and the patients had overall less fractures in the oral studies.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.